|1.||Uckun, Fatih M: 7 articles (01/2010 - 06/2002)|
|2.||Qazi, Sanjive: 4 articles (01/2010 - 01/2007)|
|3.||Uckun, F M: 4 articles (09/2001 - 01/2001)|
|4.||Liu, X P: 4 articles (09/2001 - 01/2001)|
|5.||Dibirdik, Ilker: 3 articles (01/2010 - 01/2010)|
|6.||Vassilev, Alexei: 2 articles (02/2008 - 01/2007)|
|7.||Waurzyniak, B: 2 articles (09/2001 - 05/2001)|
|8.||Lee, Sun-Hwa: 1 article (01/2013)|
|9.||Ahn, Min: 1 article (01/2013)|
|10.||Kim, Suhn Hee: 1 article (01/2013)|
01/01/2010 - "These experimental results demonstrate that the nanotechnology-enabled delivery of WHI-P131 shows therapeutic potential against leukemias with constitutive activation of the JAK3-STAT3/STAT5 molecular target."
01/01/2010 - "Thus, our findings indicate a preferential role for STAT5 (not constitutively active STAT3) in proliferation of leukemia to other JAK drugs which stimulate apoptosis and decrease proliferation, WHI-P131 prevents K562 cells growth by arresting in G2/M phases of cell cycle."
01/01/2010 - "[Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131]."
06/01/2002 - "Because WHI-P131 is devoid of antileukemic activity against BCL-1 leukemia cells, this marked improvement in survival outcome was due to reduced incidence of GVHD-associated fatalities combined with sustained GVL function of the allografts in the WHI-P131 group. "
06/01/2002 - "Notably, GVHD prophylaxis with WHI-P131 plus methotrexate resulted in 100% survival of mice receiving allotransplants challenged with an otherwise invariably fatal dose of BCL-1 leukemia. "
01/01/2010 - "At a non-toxic dose level, >4 times lower than its day 30 LD(10), JANEX-1 was highly effective in preventing intestinal tumor development in Min mice, resulting in markedly improved survival outcomes. "
10/01/1999 - "The high potency and selectivity of WHI-P131 for JAK3 makes it a promising candidate for new treatment strategies against ALL, the most common form of childhood cancer. "
01/01/2010 - "The effects of the rationally designed JAK3 inhibitor JANEX-1 on the development of intestinal tumors in the APC(min) mouse model of familial adenomatous polyposis were examined. "
06/01/1999 - "Potent and specific inhibitors of JAK3 such as WHI-P131 may provide the basis for the design of new treatment strategies against acute lymphoblastic leukemia, the most common form of childhood cancer."
01/01/2007 - "The effects of the rationally-designed Janus kinase 3 (JAK3) inhibitor JANEX-1 (4-(4'-hydroxyphenyl) amino-6,7-dimethoxy-quinazoline, WHI-P131, CAS 202475-60-3) on the development of intestinal tumors in the APC (min/+) mouse model of FAP were examined. "
01/01/2010 - "Prophylactic WHI-P131 exhibited significant anti-inflammatory activity in the SKH-1 mouse model of sunburn and afforded significant protection against the inflammatory skin damage that results from UVB exposure. "
08/01/2007 - "JANEX-1/WHI-P131 is a rationally designed novel JAK3 inhibitor with potent anti-inflammatory activity in several cellular and in vivo animal models of inflammation, including mouse models of peritonitis, colitis, cellulitis, sunburn, and airway inflammation with favorable toxicity and pharmacokinetic profile. "
|5.||Melanoma (Melanoma, Malignant)
06/01/1999 - "WHI-P131 induced apoptosis in JAK3-expressing human leukemia cell lines NALM-6 and LC1;19 but not in melanoma (M24-MET) or squamous carcinoma (SQ20B) cells. "
01/01/2010 - "The current study examined the chemopreventive potential of the dual-function JAK3/EGFR tyrosine kinase inhibitor WHI-P131 (CAS 202475-60-3) in photocarcinogenesis of non-melanoma skin cancer (NMSC). "
06/01/1999 - "WHI-P131 inhibited the clonogenic growth of JAK3-positive leukemia cell lines DAUDI, RAMOS, LC1;19, NALM-6, MOLT-3, and HL-60 (but not JAK3-negative BT-20 breast cancer, M24-MET melanoma, or SQ20B squamous carcinoma cell lines) in a concentration-dependent fashion. "
|1.||Thromboplastin (Tissue Factor)
|2.||Janus Kinase 3
|3.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|5.||alpha- cyano- (3,4- dihydroxy)- N- benzylcinnamide
|9.||Epidermal Growth Factor Receptor (EGF Receptor)
|1.||Homologous Transplantation (Allograft)
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)